A5101445353- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Brain Metastases and Treatment
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
- PARP inhibition in cancer therapy
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-related skin toxicity
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Estrogen and related hormone effects
- Radiomics and Machine Learning in Medical Imaging
Samsung Medical Center
2016-2025
Sungkyunkwan University
2016-2025
Samsung (South Korea)
2017-2024
Universidad Europea
2024
Duksung Women's University
2023
Seoul Medical Center
2020-2023
AstraZeneca (Singapore)
2021
Merck (Germany)
2021
Merck & Co., Inc., Rahway, NJ, USA (United States)
2021
MSD K.K. (Japan)
2021
Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients early triple-negative breast cancer. Whether the addition of to neoadjuvant chemotherapy would significantly increase percentage cancer who have a pathological complete response (defined as no invasive negative nodes) at definitive surgery is unclear.
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and cytotoxic topoisomerase I inhibitor. In phase 1 dose-finding study, majority the patients with advanced HER2-positive breast cancer had response to trastuzumab (median duration, 20.7 months). The efficacy in metastatic previously treated emtansine requires confirmation.In this two-part, open-label, single-group,...
Abstract Single-cell transcriptome profiling of tumour tissue isolates allows the characterization heterogeneous cells along with neighbouring stromal and immune cells. Here we adopt this powerful approach to breast cancer analyse 515 from 11 patients. Inferred copy number variations single-cell RNA-seq data separate carcinoma non-cancer At a resolution, display common signatures within as well intratumoral heterogeneity regarding subtype crucial cancer-related pathways. Most are cells,...
The addition of pembrolizumab to neoadjuvant chemotherapy led a significantly higher percentage patients with early triple-negative breast cancer having pathological complete response (defined as no invasive in the and negative nodes) at definitive surgery an earlier analysis this phase 3 trial adjuvant therapy. primary results regarding event-free survival have not been reported.
AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of inhibitor capivasertib, as an addition to fulvestrant therapy, patients with hormone receptor-positive advanced breast cancer are limited.
Purpose This study aims to evaluate the impact of chemotherapy-induced alopecia (CIA) distress on body image, psychosocial well-being, and depression among breast cancer patients. Methods A cross-sectional survey was conducted at advocacy events held 16 hospitals in Korea. Alopecia assessed using 'Chemotherapy-Induced Distress Scale', image well-being were measured by European Organization for Research Treatment Cancer Quality Life Questionnaire Core 30 specific module (BR23), Center...
Accurate detection of genomic alterations using high-throughput sequencing is an essential component precision cancer medicine. We characterize the variant allele fractions (VAFs) somatic single nucleotide variants and indels across 5095 clinical samples profiled a custom panel, CancerSCAN. Our results demonstrate that significant fraction clinically actionable have low VAFs, often due to tumor purity treatment-induced mutations. The percentages mutations under 5% VAF hotspots in EGFR, KRAS,...
Abstract Breast cancer (BC) in the Asia Pacific regions is enriched younger patients and rapidly rising incidence yet its molecular bases remain poorly characterized. Here we analyze whole exomes transcriptomes of 187 primary tumors from a Korean BC cohort (SMC) pre-menopausal perform systematic comparison with primarily Caucasian post-menopausal (TCGA). SMC harbors higher proportions HER2+ Luminal B subtypes, lower proportion A decreased ESR1 expression compared to TCGA. We also observe...
Abstract Breast cancer is the most commonly diagnosed worldwide and one of leading causes death. The incidence, pathological features, clinical outcomes in breast differ by geographical distribution across racial ethnic populations. Importantly, diversity trials lacking, with both Blacks Hispanics underrepresented. In this forum article, researchers from globe discuss factors contributing to disparities highlight specific implications precision oncology approaches for equitable provision...
Abstract DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We present a subgroup of 24 history treated brain metastases (BM), population limited treatment options. In BMs, the confirmed objective response rate (cORR) was 58.3% [95% confidence interval (CI), 36.6%–77.9%], and median progression-free survival (mPFS) 18.1 months (95% CI, 6.7–18.1 months). without BMs (n = 160), cORR...
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival addition of pembrolizumab to platinum-containing chemotherapy. Here we report final results for overall survival.
Abstract Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition would improve estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER + /HER2 − ) cancer remains unclear. We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) which previously untreated ER grade high-risk invasive (T1c-2 (≥2 cm), cN1–2 or T3–4,...
Abstract To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcriptome profiling coupled with histopathology analyses a longitudinal breast cancer cohort 146 patients including 110 pairs serial tumor biopsies collected before treatment, after first cycle treatment and at time surgery. Here, show that cytotoxic chemotherapies induce dynamic changes in immune microenvironment vary by subtype pathologic response. Just one induces an stimulatory harboring more...
Abstract Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) open-label, international, multicenter, phase 2 study of T-DXd in patients positive metastatic breast cancer (MBC) supported regulatory approval the US Japan. Updated longer-term safety efficacy results are presented here. Methods All were required to have MBC that...
Abstract Background: T-DXd is a HER2-targeting antibody-drug conjugate approved for the treatment of pts with advanced HER2+ mBC based on DESTINY-Breast01 study (NCT03248492). DESTINY-Breast03 (NCT03529110) isa randomized, multicenter, open-label, phase 3 assessing efficacy and safety vs. T-DM1 in previously treated trastuzumab taxane. In primary analysis, demonstrated clinically meaningful statistically significant improvement PFS (Corteset al, ESMO 2021). this exploratory we provide...
503 Background: KEYNOTE-522 (NCT03036488) tested the benefit from adding pembrolizumab (pembro) to chemotherapy (chemo) in patients (pts) with early TNBC. The primary results showed statistically significant and clinically meaningful improvements pCR EFS pembro.Prior studies have shown prognostic value of residual cancer burden (RCB) method quantify extent disease after neoadjuvant chemo. In this exploratory analysis, we assessed by RCB KEYNOTE-522. Methods: 1174 pts previously untreated,...
Abstract Background Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC); however, resistance common and poorly understood. A comprehensive genomic transcriptomic analysis of pretreatment post-treatment tumors from receiving palbociclib ET was performed to delineate molecular mechanisms drug resistance. Methods Tissue...
In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared those receiving treatment of physician's choice. We present the patient-reported outcomes (PROs) hospitalisation data.